by Dennis Falzon, Elizabeth Harausz, Ernesto Jaramillo et al.
World Health Organization, 2016
64 pp. 394 kB
The WHO treatment guidelines for drug-resistant tuberculosis (2016 update) contains policy recommendations on priority areas in the treatment of drug-resistant tuberculosis. The revision is in accordance with the WHO requirements for the formulation of evidence-informed policy.
The main novelties of the 2016 WHO guidelines are:
- a shorter MDR-TB treatment regimen is recommended under specific conditions;
- medicines used in the design of conventional MDR-TB treatment regimens are now reclassified to reflect updates in the evidence on their effectiveness and safety;
- specific recommendations are made on the treatment of children with rifampicin-resistant or MDR-TB based on a first-ever individual patient data meta-analysis;
- recommendations on the role of surgery in MDR-TB case management are included.